X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-idelalisib-1652172175.pdf
https://www.fiercebiotech.com/biotech/incyte-pulls-fda-filing-for-cancer-drug-approval-over-confirmatory-study-following-gilead
https://www.biospace.com/article/gilead-withdraws-cancer-drug-amidst-uncompleted-follow-up-trials-/
https://endpts.com/failing-to-confirm-clinical-benefit-gilead-pulls-2-accelerated-approval-indications-for-cancer-drug/
https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-withdraws-use-zydelig-treat-two-types-cancer-2022-01-14/
https://www.fiercepharma.com/marketing/watch-out-gilead-tg-therapeutics-has-won-fda-nod-for-a-potentially-safer-pi3k-drug-than
https://endpts.com/micro-cap-mei-pharma-lands-100m-upfront-on-beleaguered-pi3k-pathway/
https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/
https://www.biopharmadive.com/news/pharming-deal-novartis-cancer-drug-pi3k-immune/561007/
https://www.biospace.com/article/adc-therapeutics-adds-103-million-to-series-e-to-total-303-million/
https://www.biospace.com/article/astrazeneca-has-dazzled-in-recent-cancer-trials-but-faces-stiff-competition/
https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-sets-imbruvica-its-sights-promising-solo-cll-data
https://www.fiercepharma.com/pharma/az-s-calquence-chases-imbruvica-new-phase-3-leukemia-data
https://www.fiercebiotech.com/biotech/novartis-pi3k-drug-hits-goal-phase-3-breast-cancer-trial-laying-groundwork-for-talks
https://endpts.com/novartis-just-boasted-of-a-big-phiii-pi3k-success-but-heres-why-we-should-hold-our-applause-for-now/
https://pharmaphorum.com/news/novartis-success-breast-cancer-inhibitor/
https://endpts.com/novartis-punts-a-late-stage-pi3k-drug-with-a-worrying-safety-profile-to-one-of-chinas-upstart-biotechs/
https://www.fiercebiotech.com/biotech/novartis-hands-off-buparlisib-to-china-s-adlai-noryte
https://endpts.com/popular-diet-set-to-be-tested-in-humans-to-see-if-it-can-amp-up-effect-of-weak-pi3k-drugs/
https://www.fiercebiotech.com/biotech/asco18-roche-punts-taselisib-after-weak-data-severe-side-effects
https://endpts.com/roche-dumps-its-phiii-pi3k-effort-on-taselisib-after-researchers-track-poor-survival-edge-harsh-side-effects-for-breast-cancer/
https://www.fiercebiotech.com/biotech/morphosys-seeks-150m-ipo-to-fund-late-phase-anti-cancer-push
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002907.jsp&mid=WC0b01ac058004d5c1
https://endpts.com/sanuj-ravindran-to-lead-pellepharm-as-ceo-paul-hastings-leaves-oncomed-moderna-taps-john-mendlein-as-president/
http://www.fiercepharma.com/marketing/hemo-oncology-newbie-bayer-gears-up-for-copanlisib-launch
http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/zydelig-eng.php
http://www.dddmag.com/article/2017/01/gilead-hires-alessandro-riva-lead-oncology-r-d-efforts
https://www.statnews.com/pharmalot/2016/11/21/leukemia-drug-prices/
http://www.fool.com/investing/2016/11/16/3-potential-acquisition-targets-for-gilead-science.aspx?
http://www.bostonglobe.com/business/2016/11/02/beaten-down-biotechs-pin-hopes-drug-licensing-deal/hwhtcxKF0edkNWfkJ2LDZM/story.html?
http://www.pmlive.com/pharma_news/abbvie_and_roches_leukaemia_drug_venetoclax_nears_eu_market_1167280
http://www.bloomberg.com/news/articles/2016-05-06/gilead-new-ceo-says-it-s-time-to-go-out-and-do-important-deals
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58118a-eng.php
http://www.statnews.com/pharmalot/2016/03/17/gilead-cancer-hepatitis-c/
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/57590a-eng.php
http://www.pharmatimes.com/Article/16-03-14/Gilead_s_Zydelig_under_scrutiny_in_Europe_on_safety_concerns.aspx?
http://www.reuters.com/article/gilead-sciences-cancer-europe-idUSL5N16J4ZV?rpc=401
http://www.fiercepharma.com/story/ema-puts-gileads-zydelig-under-lens-after-deaths-crop-trials/2016-03-11
http://www.pmlive.com/pharma_news/opdivo_backed_for_two_new_uses_by_chmp_943732
http://www.biospace.com/News/gileads-new-ceo-john-milligan-hints-at-probable/409188/source=TopBreaking
http://www.fiercepharmamarketing.com/story/can-new-phiii-data-help-gileads-zydelig-stage-comeback-cll/2015-12-09
http://www.forbes.com/sites/elaineschattner/2015/12/09/venetoclax-is-a-powerful-new-kind-of-cancer-drug-effective-in-chronic-lymphocytic-leukemia/?ss=pharma-healthcare
http://www.reuters.com/article/2015/11/16/us-gilead-leukemia-idUSKCN0T520W20151116
http://www.pmlive.com/pharma_news/nice_gives_nod_to_gileads_zydelig_828145
http://www.pharmatimes.com/Article/15-06-18/NICE_asks_for_more_info_on_Gilead_s_Zydelig.aspx
http://images.info.science.thomsonreuters.biz/Web/ThomsonReutersScience/%7B7e677448-1313-40ae-9978-6be1a8532a08%7D_A4_MarketInsight_Report_0213_012__edits_2.pdf
http://www.pharmatimes.com/Article/15-03-09/Scotland_OKs_seven_new_drugs_for_NHS_use.aspx
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/02/news_detail_002277.jsp&mid=WC0b01ac058004d5c1
Market Place
Share 
